Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Enfortumab vedotin-ejfv||Padcev||AGS-22ME||Padcev (enfortumab vedotin-ejfv) is an antibody drug conjugate that fuses together a human antibody against NECTIN4 and monomethyl auristatin E, which may result in inhibition of tumor growth and tumor regression (PMID: 27013195). Padcev (enfortumab vedotin-ejfv) is FDA approved for use in patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||transitional cell carcinoma||not applicable||Enfortumab vedotin-ejfv||FDA approved||Actionable||In a Phase II trial (EV-201) that supported FDA approval, Padcev (enfortumab vedotin-ejfv) treatment resulted in an objective response rate of 42% (53/125) with complete response in 9% (11/125) of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy (Journal of Clinical Oncology 37, no. 18_suppl (June 20, 2019) 4505-4505; NCT03219333).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03219333||Phase II||Enfortumab vedotin-ejfv||A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)||Active, not recruiting|
|NCT03474107||Phase III||Enfortumab vedotin-ejfv Docetaxel + Paclitaxel + Vinflunine||A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)||Active, not recruiting|
|NCT04225117||Phase II||Enfortumab vedotin-ejfv||A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)||Recruiting|
|NCT02091999||Phase I||Enfortumab vedotin-ejfv||A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4||Active, not recruiting|